FKBP51: A Promising Therapeutic Target for Tauopathies
ASOs targeting FKBP51 show promise as a potential therapeutic avenue for reducing tau. The silencing of FKBP51 long-term may directly reduce tau phosphorylation and aggregation, and indirectly protect neurons from tau-mediated damage. Further optimization in vivo will commence shortly, followed by assessments in tau transgenic mice.
Authors
- Niat T. Gebru (ORCID: https://orcid.org/0000-0002-5406-1920)
- Jennifer Guergues
- Danielle Gulick (ORCID: https://orcid.org/0000-0002-5052-780X)
- Laura J. Blair (ORCID: https://orcid.org/0000-0002-4981-5564)
- Stanley M. Stevens (ORCID: https://orcid.org/0000-0002-1399-0256)
Institutions
- University of South Florida (US)
- James A. Haley Veterans' Hospital (US)
- USF Health Byrd Alzheimer's Institute (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.093126
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00